MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
26.60
-0.33
-1.23%
Pre Market: 26.80 +0.2 +0.75% 04:10 12/19 EST
OPEN
26.96
PREV CLOSE
26.93
HIGH
27.21
LOW
26.59
VOLUME
1
TURNOVER
0
52 WEEK HIGH
27.73
52 WEEK LOW
13.40
MARKET CAP
4.50B
P/E (TTM)
17.13
1D
5D
1M
3M
1Y
5Y
1D
Acadia Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Reuters · 15h ago
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Barchart · 21h ago
ACADIA PHARMACEUTICALS INC <ACAD.O>: BMO RAISES TARGET PRICE TO $34 FROM $26
Reuters · 1d ago
SA Quant ranks UBS' 26 highest conviction names for 2026
Seeking Alpha · 1d ago
New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)
Simply Wall St · 2d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
ACADIA Pharmaceuticals Price Target Raised to $37.00/Share From $32.00 by HC Wainwright & Co.
Dow Jones · 3d ago
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.